Herpetic Keratitis (HK) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Herpetic Keratitis (HK) Market Outlook

Thelansis's "Herpetic Keratitis (HK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Herpetic Keratitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Herpetic Keratitis (HK) Overview

Herpetic keratitis (HK) is a major infectious cause of corneal blindness worldwide, primarily caused by herpes simplex virus type 1 (HSV-1) and less commonly HSV-2. Following primary infection, the virus establishes latency within the trigeminal ganglion, with recurrent viral reactivation leading to progressive corneal injury and visual impairment. The disease encompasses multiple clinical forms, including epithelial keratitis, stromal keratitis, endotheliitis, and neurotrophic keratopathy, each associated with distinct pathological mechanisms and treatment approaches.

Patients commonly present with unilateral eye pain, redness, photophobia, tearing, blurred vision, and reduced corneal sensation. Recurrent disease can result in chronic corneal scarring, thinning, neovascularization, and vision loss. Diagnosis is primarily clinical through slit-lamp examination and characteristic dendritic corneal ulcers, while PCR testing may support diagnosis in atypical or severe cases.

Topical antivirals such as ganciclovir and acyclovir remain the standard treatment for epithelial disease, whereas stromal keratitis typically requires combined antiviral therapy and corticosteroids to control immune-mediated inflammation. Oral antiviral prophylaxis with acyclovir or valacyclovir is widely used to reduce recurrence risk in patients with frequent relapses. Despite available therapies, recurrent infection and immune-mediated corneal damage continue to represent significant unmet clinical challenges. The evolving treatment landscape is increasingly focused on improved antiviral strategies, neurotrophic therapies, and long-term recurrence prevention approaches aimed at preserving visual function.

Key Highlights

• In China, incident cases of herpetic keratitis are projected to increase from approximately 206,184 in 2025 to nearly 221,717 by 2035, reflecting a growing disease burden.
• Recurrent HSV reactivation remains the primary driver of progressive corneal damage and vision impairment.
• Stromal keratitis and neurotrophic keratopathy continue to represent major causes of long-term visual morbidity.
• Long-term antiviral prophylaxis plays a critical role in reducing recurrence frequency and disease progression.
• Increasing awareness, earlier diagnosis, and improved ophthalmic management are supporting better disease outcomes.

Market Overview

• The China herpetic keratitis market is projected to grow from approximately $1,024.10 MN to $2,340.50 MN by 2035, reflecting substantial market expansion.
• Market growth is supported by:
• Increasing adoption of long-term antiviral suppression therapies
• Growing demand for advanced ophthalmic treatments for recurrent and severe disease
• Market value growth is driven by rising disease recurrence, prolonged treatment duration, and increased management of vision-threatening complications.
• Future market growth will depend on next-generation antiviral therapies, regenerative corneal treatments, and improved recurrence prevention strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country